For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.
Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails
For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.